Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents: A Case Series.

Authors:
Jessica Graham
Jessica Graham
Fred Hutchinson Cancer Research Center
Michael Barberio
Michael Barberio
Children's Hospital Colorado
George Sam Wang
George Sam Wang
The Children's Hospital
United States

Pediatrics 2017 Dec 9;140(6). Epub 2017 Nov 9.

Section of Emergency Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, and.

Cannabinoid hyperemesis syndrome (CHS) is an underrecognized diagnosis among adolescents. In the adult literature, it is characterized as nausea, vomiting, and abdominal pain in patients with chronic marijuana use. CHS is often refractory to the standard treatment of nausea and vomiting. Unconventional antiemetics, such as haloperidol, have been successful in alleviating symptoms; however, even 1 dose of haloperidol can lead to grave adverse effects, such as dystonia, extrapyramidal reactions, and neuroleptic malignant syndrome. The use of topical capsaicin cream to treat CHS has been well described in the adult literature. This treatment is cost-effective and is associated with few serious side effects. Here, we describe 2 adolescent patients with nausea, vomiting, and abdominal pain in the setting of chronic cannabis use whose symptoms were not relieved by standard antiemetic therapies, but who responded well to topical capsaicin administration in our pediatric emergency department. We also discuss the pathophysiology behind capsaicin's efficacy. These are the first reported cases in which capsaicin was successfully used to treat CHS in pediatric patients.

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.2016-3795DOI Listing
December 2017
10 Reads

Publication Analysis

Top Keywords

nausea vomiting
12
cannabinoid hyperemesis
8
hyperemesis syndrome
8
abdominal pain
8
adult literature
8
vomiting abdominal
8
treat chs
8
capsaicin cream
8
topical capsaicin
8
reactions neuroleptic
4
extrapyramidal reactions
4
emergency department
4
pediatric emergency
4
neuroleptic malignant
4
malignant syndrome
4
syndrome topical
4
dystonia extrapyramidal
4
effects dystonia
4
symptoms dose
4
dose haloperidol
4

Similar Publications

Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series.

Clin Toxicol (Phila) 2017 Sep 11;55(8):908-913. Epub 2017 May 11.

b Division of Emergency Medicine , Washington University School of Medicine , Saint Louis , MO , USA.

Background: Cannabinoid hyperemesis syndrome (CHS) is characterized by symptoms of cyclic abdominal pain, nausea, and vomiting in the setting of prolonged cannabis use. The transient receptor potential vanilloid 1 (TRPV1) receptor may be involved in this syndrome. Topical capsaicin is a proposed treatment for CHS; it binds TRPV1 with high specificity, impairing substance P signaling in the area postrema and nucleus tractus solitarius via overstimulation of TRPV1. Read More

View Article
September 2017

Haloperidol for treatment of cannabinoid hyperemesis syndrome.

Am J Emerg Med 2013 Jun 10;31(6):1003.e5-6. Epub 2013 Apr 10.

Department of Emergency Medicine, Cook County Hospital, Chicago, IL, USA.

Cannabinoid hyperemesis syndrome (CHS) is a condition characterized by cyclical vomiting without other identifiable cause in patients with chronic cannabis use. Patients with CHS report that compulsive bathing and hot showers are the only reliable treatments to improve symptoms. Cannabinoid hyperemesis syndrome is usually unresponsive to conventional pharmacologic antiemetics, and patients often require hospital admission. Read More

View Article
June 2013

Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?

BMJ Case Rep 2017 Jan 4;2017. Epub 2017 Jan 4.

Shifa International Hospital, Islamabad, Pakistan.

Cannabinoid hyperemesis syndrome (CHS) is a rare clinical syndrome characterised by nausea, cyclic vomiting and severe abdominal pain in association with chronic cannabis use. It is often under-recognised or misdiagnosed, resulting in the unnecessary workup and frequent hospitalisations. Long-term treatment of CHS is abstinence from cannabis, but acute symptomatic management has been a struggle for many clinicians. Read More

View Article
January 2017

Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.

Am J Ther 2017 Jan/Feb;24(1):e64-e67

Departments of 1Emergency Medicine and 2Pharmacy, Cook County Hospital (Stroger), Chicago, IL.

Cannabinoid hyperemesis syndrome (CHS) is typically unresponsive to conventional pharmacologic antiemetics, and patients often require excessive laboratory and radiographic testing and hospital admission. We report 4 cases of CHS that failed standard emergency department therapy but improved significantly after treatment with haloperidol. Although the exact mechanism for CHS remains unclear, dysregulation at cannabinoid type 1 seems to play a role. Read More

View Article
February 2017